Market Overview

Millendo Therapeutics to Participate in September Investor Conferences


Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:

Citi's 14th Annual Biotech Conference

Date: Thursday, September 5, 2019 (one-on-one meetings only)

Location: Boston, MA

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

Date: Monday, September 23, 2019 (one-on-one meetings only)

Location: New York, NY

Ladenburg Thalmann 2019 Healthcare Conference

Date/Time: Tuesday, September 24, 2019 at 11:00 a.m. EDT

Location: New York, NY

A live webcast of the Ladenburg Thalmann presentation will be available on the Investors & Media section of Millendo's website at A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at